title: Long-term interferon-alpha 2A does not induce sustained hematologic remission in younger patients with essential thrombocythemia.
abstract: The ability of Interferon alpha (alpha-IFN) to alter the natural history of essential thrombocythemia (ET) and induce sustained hematologic remission would provide further impetus to consider this agent in younger patients with this disease and may influence the decision to commence treatment in asymptomatic patients. This study has failed to demonstrate any sustained hematologic remissions after cessation of long-term (2 years) alpha-IFN administration in a group of 34 female patients with a median age of 41 years (range 14-68) who were considered at intermediate to high risk of thrombotic complications. In the twenty-one patients completing two years of therapy, 13 (62%) had complete hematological responses (CHR; platelet count <400 x 10(9)/L), 7 (33%) partial hematological responses (PHR; platelet count 400-600 x 10(9)/L) and no thrombotic or hemorrhagic complications occurred. In all patients who discontinued alpha-IFN at 2 years, platelet counts rose above the normal range within 1-4 months and the majority required reinstitution of some form of therapy. The inability of long-term alpha-IFN to induce sustained, unmaintained hematologic remission argues strongly against any significant effect on the neoplastic clone at the doses used in this study. This study does, however, confirm the efficacy of long-term alpha-IFN in younger female patients with ET, a group not previously well represented in clinical trials of the agent.
authors.affiliation: Department of Haematology, Mater Hospital, Brisbane, QLD, Australia.
authors.forename: M
authors.initials: M
authors.lastname: Bentley
authors.forename: K
authors.initials: K
authors.lastname: Taylor
authors.forename: A
authors.initials: A
authors.lastname: Grigg
authors.forename: H
authors.initials: H
authors.lastname: Kronenberg
authors.forename: J
authors.initials: J
authors.lastname: Gibson
authors.forename: I
authors.initials: I
authors.lastname: Bunce
authors.forename: P
authors.initials: P
authors.lastname: Eliadis
authors.forename: T
authors.initials: T
authors.lastname: Olsen
authors.forename: S
authors.initials: S
authors.lastname: Wright
authors.forename: D
authors.initials: D
authors.lastname: Taylor
authors.forename: R
authors.initials: R
authors.lastname: Rodwell
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008875:Middle Aged; D010976:Platelet Count / Q000187:drug effects; D011446:Prospective Studies; D011994:Recombinant Proteins; D013922:Thrombocytosis / Q000097:blood / Q000188:drug therapy*
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins